View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
June 7, 2018

eFFECTOR starts dosing in expansion portion of eFT508 Phase l/ll trial

eFFECTOR Therapeutics has started dosing patients in the Phase ll expansion portion of its ongoing Phase l/ll study of eFT508 for the treatment of relapsed, refractory, non-germinal centre B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL).

eFFECTOR Therapeutics has started dosing patients in the Phase ll expansion portion of its ongoing Phase l/ll study of eFT508 for the treatment of relapsed, refractory, non-germinal centre B cell (non-GCB) diffuse large B-cell lymphoma (DLBCL).

In this portion, patients will be given a 200mg dose of eFT508 twice daily, which was established in the Phase l dose-escalation portion of the trial.

The Phase l/ll trial is an open-label, sequential-group, dose-escalation and cohort-expansion study designed to analyse the safety, pharmacokinetics, pharmacodynamics and anti-tumour activity of eFT508 in patients with haematological malignancies.

The primary objective of the expansion cohort is the objective response rate (ORR) of eFT508 in non-GCB DLBCL patients.

eFFECTOR Therapeutics president and CEO Steve Worland said: “This Phase ll expansion cohort builds on our Phase l results, where we observed a confirmed partial response in one of two non-GCB DLBCL patients enrolled during dose escalation.

“Patients with non-GCB DLBCL who have failed other available treatment options face a devastating disease.”

“Patients with non-GCB DLBCL who have failed other available treatment options face a devastating disease.”

Non-GCB DLBCL is an aggressive form of non-Hodgkin’s lymphoma (NHL) that is partly caused by the activation of nuclear factor kappa-light-chain-enhancer of activated B-cells (NFkB) and frequently responds poorly to standard treatments.

According to the Lymphoma Research Foundation, DLBCL is estimated to account for 30% of the newly diagnosed NHL cases each year.

eFT508, an oral, small molecule inhibitor of MNK1/2, has previously secured orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of DLBCL.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena